Table 2. Characteristics of patients enrolled in the Vorinostat-based clinical trial.
| Patient n° | Sex | Age | % Blasts PB | % Blasts BM | FAB | Cyto | Mol Bio | Flow cytometry |
|---|---|---|---|---|---|---|---|---|
| 779291 | F | 56 | 90 | 62 | M2 | 46, XX | NPM1 | CD13, CD15, CD33, CD117, CD38, CD64 |
| 788122 | F | 22 | 46 | 91 | M0 | Complex | Neg | CD13, CD33, CD117, CD15, CD64 |
| 756912 | F | 21 | 96 | 86 | M2 | 46, XX | FLT3+ | CD117, ndim CD64, CD38, CD33, CD13 |
| 752322 | M | 55 | 26 | Unk | −Y | FLT3, ITD | CD13, CD2, CD117, CD33, CD34, HLADR | |
| 782077 | F | 54 | 18 | 38 | M5 | Complex | Neg | ND |
| 761339 | M | 48 | 2 | 24 | RAR EB-T | −5, −7 | ND | CD13, CD15+/-, CD117, CD34, CD38 |